Editas Medicine Inc (EDIT) support and resistance · rev $32.3M
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
This page maps Editas Medicine Inc (EDIT) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
EDIT currently screens at market cap $375.2M. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new EDIT 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the EDIT quote page for the session range and the stock page for the full model.
Not investment advice.